


Injection pens for osteoporosis therapy may contribute to greater compliance

In this whitepaper, read how Injection Pens for Osteoporosis Therapy may contribute to greater compliance



There is a need for action in osteoporosis therapy - the number of multiple fractures worldwide is too high

Brief summary: The International Osteoporosis Foundation cites figures of around 200 million osteoporosis patients worldwide. Numerous patients suffer not just one bone fracture, but several at once. Treatment does not appear to be having the best possible effect. As an experienced partner in the design and production of injection systems, Haselmeier is also well prepared in terms of injection pens for osteoporosis therapy.

Whether it be vertebral fractures, femoral neck fractures or bone fractures in the wrist: The majority of fractures caused by osteoporosis can be avoided with good and most importantly consistent treatment. However, as the study reveals, compliance among patients is often inadequate: Around 40 percent of patients stop taking their medication after just one year. And after two years, only 20 percent remain compliant with regular medication. Injection pens for osteoporosis therapy could provide a solution here, since they are very easy to use, safe, and are largely pain-free for patients.

Successes from insulin therapy could be transferable

In insulin therapy, subcutaneous self-delivery is already widespread and normal practice for patients. Numerous manufacturers have launched successful injection systems onto the market and the acceptance among patients of subcutaneous self-delivery is high. For this reason, injection pens for osteoporosis therapy could also be a route towards significantly improving treatment efficiency. Of the twelve most commonly prescribed medications, two active ingredients are already available in injection pen form for osteoporosis treatment. The active ingredients, which are used to fight osteoporosis, are intended to either prevent further bone destruction or encourage new bone growth.

Haselmeier is also an experienced development partner in the field of injection pens for osteoporosis therapy

Innovative medication dosing systems for subcutaneous self-delivery are Haselmeier's core mission. The company especially concentrates on assisting customers in the development phase and with market development. A flexible scale-up concept ensures that customer requirements and

patient needs can be served and addressed in equal measure. Haselmeier's array of services completes its portfolio, with the company about to hold a pharmaceutical packaging license, for example, enabling them to produce small and medium-sized volumes. These are primarily required for clinical studies and early developmental stages by customers from the worlds of pharmacy and biotechnology.

As a reliable partner, Haselmeier also facilitates a modular approach for the development and production of injection pens for osteoporosis therapy. As a result, the entire process - from the development and production of pens to timely market supplies - is taken care of from a single source. Worldwide, Haselmeier impresses its customers with treatment reliability through individual injection systems, and inspires with its scalability and intelligent control and monitoring.



Wilhelm Haselmeier
GmbH & Co. KG

Dr. Fred Metzmann,
Chief Business Officer

Vaihinger Straße 48
70567 Stuttgart / Germany
Phone +49 711 719 78 163

Wilhelm Haselmeier GmbH & Co. KG, a business unit of the Haselmeier Group, is active in the medical field. Content provided in various formats provides general information about the status of developments and products and is aimed exclusively at a specialist audience. This information does not replace counseling.

www.haselmeier.com

Sitz: Stuttgart / registered court Stuttgart - HRA 2553 personally liable shareholder:
Gabriel Consult GmbH / General Manager: Gert Weber, Mark Bleckmann
Sitz: Stuttgart / registered court Stuttgart - HRB 11020

